Reply by Authors.

Autor: Shore N; Carolina Urologic Research Center, Myrtle Beach, South Carolina., Pieczonka C; Associated Medical Professionals, Syracuse, New York., Heron S; Advanced Urology Institute, St Petersburg, Florida., Gazi M; University Urology Associates of New Jersey, Hamilton, New Jersey., Cahn D; Colorado Urology, Lakewood, Colorado., Belkoff LH; MidLantic Urology, Bala Cynwyd, Pennsylvania., Berger A; Associated Urological Specialists, Chicago Ridge, Illinois., Mazzarella B; Urology Austin, Austin, Texas., Veys J; North Georgia Urology, Dalton, Georgia., Idom C; North Georgia Urology, Dalton, Georgia., Morris D; Urology Associates, PC, Nashville, Tennessee., Jayram G; Urology Associates, PC, Nashville, Tennessee., Engelman A; Florida Urology Partners, Cancer Center of South Tampa, St Petersburg, Florida., Dato P; Genesis Healthcare Partners, San Diego, California., Bevan-Thomas R; Urology Partners, Arlington, Texas., Wise DR; Perlmutter Cancer Center, NYU Langone Health, New York, New York., Hardwick MK; Medical Affairs, Invitae Corp, San Francisco, California., Rojahn S; Medical Affairs, Invitae Corp, San Francisco, California., Layman P; Medical Affairs, Invitae Corp, San Francisco, California., Heald B; Medical Affairs, Invitae Corp, San Francisco, California., Ellsworth RE; Medical Affairs, Invitae Corp, San Francisco, California., Hatchell KE; Medical Affairs, Invitae Corp, San Francisco, California., Nussbaum RL; Medical Affairs, Invitae Corp, San Francisco, California.; Division of Medical Genetics, Department of Pediatrics, University of California, San Francisco, San Francisco, California., Nielsen SM; Medical Affairs, Invitae Corp, San Francisco, California., Esplin ED; Medical Affairs, Invitae Corp, San Francisco, California.

Publikováno v: The Journal of urology [J Urol] 2024 Dec; Vol. 212 (6), pp. 842-843. Date of Electronic Publication: 2024 Sep 03.

Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.

Autor: Shore N; Carolina Urologic Research Center, Myrtle Beach, SC, USA. Electronic address: nshore@auclinics.com., Gazi M; University Urology Associates of New Jersey, Hamilton, NJ, USA., Pieczonka C; Associated Medical Professionals, Syracuse, NY, USA., Heron S; Advanced Urology Institute, St. Petersburg, FL, USA., Modh R; Advanced Urology Institute, St. Petersburg, FL, USA., Cahn D; Colorado Urology, Lakewood, CO, USA., Belkoff LH; MidLantic Urology, Bala Cynwyd, PA, USA., Berger A; Associated Urological Specialists, Chicago Ridge, IL, USA., Mazzarella B; Urology Austin, Austin, TX, USA., Veys J; North Georgia Urology, Dalton, GA, USA., Idom C; North Georgia Urology, Dalton, GA, USA., Morris D; Urology Associates, P.C., Nashville, TN, USA., Jayram G; Urology Associates, P.C., Nashville, TN, USA., Engelman A; TGH Cancer Institute, Tampa, FL, USA., Bukkapatnam R; Florida Urology Partners, Tampa, FL, USA., Dato P; Genesis Healthcare Partners, San Diego, CA, USA., Bevan-Thomas R; Urology Partners, Arlington, TX, USA., Cornell R; Urosurgery Houston, Houston, TX, USA., Wise DR; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Hardwick MK; Invitae Corporation, San Francisco, CA, USA., Hernandez RD; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA., Rojahn S; Invitae Corporation, San Francisco, CA, USA., Layman P; Invitae Corporation, San Francisco, CA, USA., Hatchell KE; Invitae Corporation, San Francisco, CA, USA., Heald B; Invitae Corporation, San Francisco, CA, USA., Nussbaum RL; Invitae Corporation, San Francisco, CA, USA; Volunteer Faculty, University of California San Francisco, San Francisco, CA, USA., Nielsen SM; Invitae Corporation, San Francisco, CA, USA., Esplin ED; Invitae Corporation, San Francisco, CA, USA.

Publikováno v: European urology oncology [Eur Urol Oncol] 2023 Oct; Vol. 6 (5), pp. 477-483. Date of Electronic Publication: 2023 Aug 12.

A Rare Case of Signet Ring Cell Carcinoma of the Colon With Selective Metastasis to the Prostate.

Autor: Park JJ; Philadelphia College of Osteopathic Medicine, Philadelphia, PA. Electronic address: jp246804@pcom.edu., Snow ZA; Department of Urology, Main Line Health, Bryn Mawr, PA., Lurz KL; Department of Urology, Main Line Health, Bryn Mawr, PA., Edwards DC; Department of Urology, Main Line Health, Bryn Mawr, PA., Belkoff LH; Department of Urology, Main Line Health, Bryn Mawr, PA., Cahn DB; Department of Urology, Main Line Health, Bryn Mawr, PA.

Publikováno v: Urology [Urology] 2020 Sep; Vol. 143, pp. e17-e19. Date of Electronic Publication: 2020 Jun 04.

A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.

Autor: Donin NM; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA. Electronic address: NDonin@mednet.ucla.edu., Chamie K; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA., Lenis AT; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA., Pantuck AJ; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA., Reddy M; Division of Urology, Hahnemann University Hospital, Philadephia, PA., Kivlin D; Division of Urology, Hahnemann University Hospital, Philadephia, PA., Holldack J; Telormedix SA, Bioggio, Switzerland., Pozzi R; Telormedix SA, Bioggio, Switzerland., Hakim G; UroGen Pharma, Ra'anana, Israel., Karsh LI; The Urology Center of Colorado, Denver, CO., Lamm DL; BCG Oncology, Phoenix, AZ., Belkoff LH; Division of Urology, Hahnemann University Hospital, Philadephia, PA., Belldegrun AS; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA., Holden S; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA., Shore N; Carolina Urologic Research Center, Myrtle Beach, SC.

Publikováno v: Urologic oncology [Urol Oncol] 2017 Feb; Vol. 35 (2), pp. 39.e1-39.e7. Date of Electronic Publication: 2016 Oct 26.

A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy.

Autor: Bianco FJ; Urological Research Network, Miami, Florida., Albala DM; Associated Medical Professionals, Syracuse, New York., Belkoff LH; Urologic Consultants of Southeastern Pennsylvania, Bala Cynwyd, Pennsylvania., Miles BJ; Houston Methodist Research Institute, Houston, Texas., Peabody JO; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan., He W; Astellas, Northbrook, Illinois., Bradt JS; Astellas, Northbrook, Illinois., Haas GP; Astellas, Northbrook, Illinois., Ahlering TE; UC Irvine, Orange, California.

Publikováno v: The Journal of urology [J Urol] 2015 Apr; Vol. 193 (4), pp. 1305-10. Date of Electronic Publication: 2014 Oct 02.